Senses Disorder TRIZ Cases

Topical SkQ antioxidants target oxidative stress in dry eye patients with Schirmer scores ≥7 mm, improving corneal health and visual acuity.

Local lenvatinib blocks VEGF and TGF-beta driven fibrosis to reduce scarring, collagen formation, and bleb failure after eye surgery.

Fully human antibodies block glucagon receptor binding to lower blood glucose for at least 7 days while reducing immunogenicity.

IL-36 and IL-18 compositions strengthen the endothelial barrier to reduce ocular vascular leakage without direct anti-VEGF blockade.

A 100-400 bp retinal cell-specific promoter preserves high gene expression while fitting AAV packaging limits and reducing off-target effects.

A phase-changing polymer implant localizes retinal therapy, enabling controlled dosing with lower immunogenicity and less invasive delivery.

Local PDE inhibitor delivery raises cyclic nucleotide levels in nasal and salivary mucus to restore smell and taste with low systemic exposure.

Humanized anti-PVR antibodies optimize CDR and framework regions to improve binding, reduce immunogenicity, and boost T and NK cell tumor killing.

Codon-optimized CFI boosts protein expression at lower vector doses, reducing tissue damage and off-target effects in AMD gene therapy.

Genetic testing links AMD variants to intraretinal fluid, visual acuity, and dosing frequency for more tailored anti-VEGF treatment.

Blocking BTC alongside VEGF reduces retinal vascular permeability and may improve response in ophthalmic patients with limited anti-VEGF benefit.

Transient OCT4, SOX2, and KLF4 expression reverses epigenetic aging while preserving cellular identity and avoiding teratoma risk.

MASP-2 inhibitors block lectin-pathway complement activation at initiation, reducing tissue injury while preserving the classical pathway.

Distinct BTK inhibitor polymorphs, solvates, and salts improve solid-state stability and solubility for more reliable therapeutic formulation.

Structural changes at the 1-position of 2-bromo lysergamides reduce hallucinogenic effects while preserving therapeutic activity.

Drug-loaded hydrogel particles within a surrounding hydrogel sustain ocular release while keeping implant volume low and biocompatibility high.

Cyclin D1 elevation plus p27Kip1 knockdown expands Müller glia before differentiation, supporting retinal regeneration without depleting MG cells.

Hydrazide-containing CRM1 modulators maintain systemic exposure and inhibition efficacy while reducing toxicity, side effects, and brain penetration.

Freeze-dried PRP without cryopreservatives preserves a high share of primed platelets for long-term storage and regenerative release after reconstitution.

High sialic acid loading helps an IgE Fc receptor dimer bind IgE strongly, stay longer in blood, and avoid Fc gamma receptor side effects.

A pentadecanoic acid triglyceride composition helps protect retinal tissue by inhibiting ER stress, abnormal protein buildup, and cell death.

Engineered CDR sequences give anti-VEGF monoclonal antibodies stronger VEGF165 selectivity, inhibiting angiogenesis with lower toxicity.

A formula I small-molecule scaffold expands CCR6 antagonist options with strong activity and favorable PK/PD for inflammatory disease treatment.

Codon-optimized anti-VEGF scFv delivered by AAV boosts ocular expression and reduces dosing frequency for neovascular eye diseases.

Embedding carotenoids in gelling wall materials improves light, oxygen, and heat stability while lowering pigment dissolution and staining.

Novel indanone derivatives address weak picornavirus drug efficacy by combining broad antiviral activity with low cytotoxicity.

Structurally tuned RIPK1 inhibitors improve control of apoptosis and inflammation while reducing off-target toxicity in disease treatment.

Specific ibrutinib polymorphs and solvates use XRPD-defined crystal forms to improve stability and preserve BTK inhibitor efficacy.

Higher-solubility isocyclosporin A enables topical ocular treatment without surfactants, improving bioavailability while reducing corneal damage.

A single rAAV8 retinal injection enables continuous anti-VEGF Fab expression, reducing repeat wet AMD injections and recurrence risk.

Structured purine dione variants tune Wnt pathway inhibition to treat cancer and fibrosis while limiting disruption of stem cell maintenance.

A defined mesenchymal cell population detaches as an intact cell sheet without trypsin, reducing cell damage and production cost.

Orally administered Bacillus-derived superoxide dismutase reduces retinal vascular leakage and inflammation in diabetic retinopathy and uveitis.

Nitrogen-containing bridged heterocycles selectively bind Factor B to inhibit the alternative complement pathway with promising pharmacokinetics.

A calibrated chamber and plunger meter repeatable small doses of semi-solid pharmaceuticals while limiting contamination and degradation.

Oral nicotinamide lowers elevated intraocular pressure, improves treatment compliance, and offers a less invasive prophylactic option.

Multi-agent keratolytic conjugates target inflammation, immune dysregulation, and epithelial causes of dry eye in one topical treatment.

A biodegradable core-shell microparticle uses electrostatic drug loading and shell-controlled degradation to extend ocular release and reduce injection frequency.

Multimerized VEGF antagonists use Fc and optional IgM tailpiece domains to extend ocular dosing intervals while maintaining efficacy.

Small-molecule hydroquinazolines activate NPR1 to replace infusion-based ANP therapy with oral treatment for heart failure and hypertension.

Specific capsid amino acid changes improve AAV delivery into deeper retinal cell types, expanding gene transfer across the retina.

Specific variable-region sequence changes improve C5 binding, extend serum half-life, and reduce dosing frequency in C5-related disease treatment.

Sequential stem cell differentiation yields homogeneous photoreceptor progenitors that mature into functional retinal cells for therapy.

A topical ophthalmic composition inhibits intraocular vascular leakage while reducing repeat dosing, pain, and side effects in eye disease treatment.

Blocking MASP-1, MASP-2, and MASP-3 at complement initiation helps limit tissue damage where downstream C5 inhibition is insufficient.

Trans-splicing RNA editors overcome ABCA4 gene size limits and broad mutation diversity to restore protein function in retinal dystrophies.

A tear-mimicking lipid formulation forms a stable ocular film to reduce evaporation, improve lubrication, and relieve dry eye symptoms.

A cone opsin and GIRK1 F137S gene therapy restores light sensitivity in degenerating cones without microbial opsins, supporting acuity and color vision.

A sustained ocular delivery platform combines pressure-lowering and neuroprotective agents to treat glaucoma beyond short-term IOP control.

Bypassing surgical ear delivery, intranasal BDNF reaches the inner ear through the olfactory pathway to treat sensorineural hearing loss.